FI
CRVS icon

Fosun International’s Corvus Pharmaceuticals CRVS Stock Holding History

Fosun International’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-184,116
Closed -$624K – 254
2019
Q2 		$624K Buy
184,116
+13,142
+8% +$51.5K 0.04% 206
2019
Q1 		$669K Buy
170,974
+11,992
+8% +$50.6K 0.04% 197
2018
Q4 		$523K Buy
+158,982
New +$1.08M 0.03% 216

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fosun International's CRVS Position: Q3 2019 in Review

Fosun International sold out of Corvus Pharmaceuticals (CRVS) in Q3 2019, closing a stake of 184,116 shares — an estimated $624K sold.

Fosun International first reported a position in CRVS in Q4 2018 and held it in 3 quarters. The position peaked at $669K in Q1 2019. 35 funds tracked by Wall St. Rank hold CRVS as of Q3 2019.

  • Fosun International reported no remaining Corvus Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
  • Fosun International sold 184,116 Corvus Pharmaceuticals shares in Q3 2019, an estimated $624K.
  • Fosun International first reported a position in Corvus Pharmaceuticals in Q4 2018 and held it in 3 quarters.
  • Fosun International's Corvus Pharmaceuticals position peaked at $669K in Q1 2019.
  • 35 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q3 2019.

Based on Fosun International's 13F filing for Q3 2019, filed 12 Nov 2019.